{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:47:19Z","timestamp":1791316039275,"version":"4.3.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jpba.2022.115045","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T02:30:32Z","timestamp":1663036232000},"page":"115045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Identification and characterization of forced degradation products of sertraline hydrochloride using UPLC, ultra-high-performance liquid Chromatography-Quadrupole-Time of flight mass spectrometry (UHPLC-Q-TOF\/MS\/MS) and NMR"],"prefix":"10.1016","volume":"221","author":[{"given":"Parul","family":"Grover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debaraj","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2022.115045_bib1","first-page":"195","article-title":"Determination of sertraline in human plasma by UPLC\u2013MS\/MS and its application to a pharmacokinetic study","volume":"54","author":"Yue","year":"2016","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2022.115045_bib2","first-page":"46","article-title":"Sertraline: a new antidepressant","volume":"49","author":"Doogan","year":"1988","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpba.2022.115045_bib3","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.2174\/092986712800099749","article-title":"Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions","volume":"19","author":"Mandrioli","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jpba.2022.115045_bib4","first-page":"542","article-title":"Metabolism and disposition of the 5-Hydroxytryptamine uptake blocker abstract: Sertraline in the rat and dog","author":"Tremaine","year":"1989","journal-title":"J. Pharmacol. Exp. Ther. 17"},{"key":"10.1016\/j.jpba.2022.115045_bib5","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1002\/jssc.201200586","article-title":"Determination of sertraline in rat plasma by HPLC and fluorescence detection and its application to in vivo pharmacokinetic studies","volume":"35","author":"Melis","year":"2012","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2022.115045_bib6","first-page":"768","article-title":"The role of sertraline in the management of depression","volume":"16","author":"Shelton","year":"1994","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jpba.2022.115045_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1871524910909030197","article-title":"Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship","volume":"9","author":"Hashimoto","year":"2009","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.jpba.2022.115045_bib8","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2165\/00003088-200241150-00002","article-title":"Clinical pharmacokinetics of sertraline","volume":"41","author":"De Vane","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2022.115045_bib9","first-page":"195","article-title":"Determination of sertraline in human plasma by UPLC\u2013MS\/MS and its application to a pharmacokinetic study","volume":"54","author":"Yue","year":"2016","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2022.115045_bib10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jchromb.2006.03.026","article-title":"HPLC analysis of the second-generation antidepressant sertraline and its main metabolite N-desmethylsertraline in human plasma","volume":"836","author":"Mandrioli","year":"2006","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2022.115045_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/chrsci\/49.2.89","article-title":"Development and validation of an improved method for the quantitation of sertraline in human plasma using LC-MS-MS and its application to bioequivalence studies","volume":"49","author":"Zhang","year":"2011","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2022.115045_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.mex.2022.101750","article-title":"Development of UPLC-MS\/MS method and its pharmacokinetic application for estimation of sertraline in rat plasma","volume":"9","author":"Rahman","year":"2022","journal-title":"MethodsX"},{"key":"10.1016\/j.jpba.2022.115045_bib13","first-page":"543","article-title":"Determination of sertraline and its metabolite by high-pressure liquid chromatography in plasma","volume":"60","author":"Nazan","year":"2015","journal-title":"Rev. Roum. Chim."},{"key":"10.1016\/j.jpba.2022.115045_bib14","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1002\/jssc.201200586","article-title":"Determination of sertraline in rat plasma by HPLC and fluorescence detection and its application to in vivo pharmacokinetic studies","volume":"35","author":"Melis","year":"2012","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2022.115045_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jchromb.2008.12.008","article-title":"Analysis of second-generation antidepressant drug, sertraline and its active metabolite, N-desmethyl sertraline in human plasma by a sensitive and selective liquid chromatography-tandem mass spectrometry method","volume":"877","author":"Patel","year":"2009","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2022.115045_bib16","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/rcm.2610","article-title":"Development and validation of a liquid chromatographic\/tandem mass spectrometric method for the determination of sertraline in human plasma","volume":"20","author":"Chen","year":"2006","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpba.2022.115045_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/2229-5186.79345","article-title":"Methods for the determination of limit of detection and limit of quantitation of the analytical methods","volume":"2","author":"Shrivastava","year":"2011","journal-title":"Chron. Young Sci."},{"key":"10.1016\/j.jpba.2022.115045_bib18","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jpha.2020.11.002","article-title":"Single-run reversed-phase HPLC method for determining sertraline content, enantiomeric purity, and related substances in drug substance and finished product","volume":"10","author":"Rosetti","year":"2020","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2022.115045_bib19","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1080\/10826076.2012.673208","article-title":"HPTLC method for analysis of sertraline in pure bulk drug and lipidic nano delivery system: a stress degradation studies","volume":"36","author":"Hussain","year":"2013","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.jpba.2022.115045_bib20","first-page":"82","article-title":"Separation of Four Impurities and Degradants by LC: A Case of Bicalutamide","volume":"41","author":"Mittal","year":"2021","journal-title":"Hacet. Univ. J. Fac. Pharm."},{"key":"10.1016\/j.jpba.2022.115045_bib21","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.talanta.2012.09.060","article-title":"Sensitive determination of sertraline by capillary electrophoresis with dispersive liquid-liquid microextraction and field-amplified sample stacking","volume":"101","author":"Huang","year":"2012","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2022.115045_bib22","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1016\/j.jchromb.2011.07.015","article-title":"Development and validation of an EI-GC\/MS method for the determination of sertraline and its major metabolite desmethyl-sertraline in blood","volume":"879","author":"Khraiwesh","year":"2011","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2022.115045_bib23","doi-asserted-by":"crossref","first-page":"958","DOI":"10.36468\/pharmaceutical-sciences.727","article-title":"Development and validation of novel and highly sensitive stability-indicating reverse phase ultra performance liquid chromatography method for quantification of ibrutinib and its ten degradation products","volume":"82","author":"Mehta","year":"2020","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2022.115045_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113768","article-title":"LC and LC\u2013MS\/MS studies for identification and characterization of new degradation products of ibrutinib and elucidation of their degradation pathway","volume":"194","author":"Mehta","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2022.115045_bib25","first-page":"1","article-title":"Identification and characterization of new degradation products of belinostat using UHPLC-Q-TOF-MS\/MS and in silico toxicity prediction","author":"Mehta","year":"2021","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.jpba.2022.115045_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114351","article-title":"LC-MS\/MS studies for identification and characterization of new forced degradation products of dabrafenib and establishment of their degradation pathway","volume":"206","author":"Grover","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2022.115045_bib27","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.5530\/ijper.56.1s.43","article-title":"Identification and characterization of in vitro metabolites of belinostat by rat liver microsomes using ultra performance liquid chromatography coupled with tandem mass spectrometry","volume":"56","author":"Grover","year":"2022","journal-title":"Indian J. Pharm. Educ. Res."},{"key":"10.1016\/j.jpba.2022.115045_bib28","first-page":"762","article-title":"Identification and characterization of in vitro metabolites of ibrutinib by rat liver microsomes using ultra performance liquid chromatography coupled with tandem mass spectrometry","volume":"84","author":"Grover","year":"2022","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2022.115045_bib29","doi-asserted-by":"crossref","first-page":"888","DOI":"10.5530\/ijper.56.3.142","article-title":"Development and validation of novel and highly sensitive stability-indicating reverse phase UPLC method for quantification of dabrafenib and its ten degradation products","volume":"56","author":"Grover","year":"2022","journal-title":"Indian J. Pharm. Educ. Res"},{"key":"10.1016\/j.jpba.2022.115045_bib30","unstructured":"Q3A (R2) ICH Impurities in new drug substances International Conference on Harmonisation (ICH). Geneva, Switzerland."},{"key":"10.1016\/j.jpba.2022.115045_bib31","unstructured":"Q3B (R2) ICH Impurities in new drug products International Conference on Harmonisation (ICH). Geneva, Switzerland."},{"key":"10.1016\/j.jpba.2022.115045_bib32","unstructured":"Q1A(R2) ICH Stability testing of new drug substances and products International Conference on Harmonisation (ICH). Geneva, Switzerland."},{"key":"10.1016\/j.jpba.2022.115045_bib33","unstructured":"Q1B ICH Photostability testing of new drug substances and products International Conference on Harmonisation (ICH). Geneva, Switzerland."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522004666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522004666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:24:07Z","timestamp":1760001847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708522004666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":33,"alternative-id":["S0731708522004666"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2022.115045","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and characterization of forced degradation products of sertraline hydrochloride using UPLC, ultra-high-performance liquid Chromatography-Quadrupole-Time of flight mass spectrometry (UHPLC-Q-TOF\/MS\/MS) and NMR","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2022.115045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115045"}}